ORCHESTRA BIOMED HOLDINGS, INC. Orchestra BioMed Holdings, Inc. Share Price
Equities
OBIO
US68572M1062
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5 USD | -1.96% |
|
+13.90% | -45.24% |
| Sales 2024 * | 3.31M 263M | Sales 2025 * | 3.9M 310M | Capitalization | 183M 14.5B |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -4.61B | Net income 2025 * | -55M -4.37B | EV / Sales 2024 * | 55.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 46.9 x |
| P/E ratio 2024 * |
-3.25
x | P/E ratio 2025 * |
-3.27
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.96% | ||
| 1 week | +13.90% | ||
| Current month | +13.38% | ||
| 1 month | +1.42% | ||
| 3 months | -30.75% | ||
| 6 months | -4.76% | ||
| Current year | -45.24% |
1 week
4.29
5.56
1 month
4.225.56
Current year
4.2210.06
1 year
4.2220.19
3 years
4.2223.39
5 years
4.2223.39
10 years
4.2223.39
| Managers | Title | Age | Since |
|---|---|---|---|
Darren Sherman
FOU | Founder | 52 | 25/01/23 |
David Hochman
CEO | Chief Executive Officer | 49 | 25/01/23 |
Andrew Taylor
DFI | Director of Finance/CFO | 53 | 05/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Rose
BRD | Director/Board Member | 73 | 25/01/23 |
Eric Fain
BRD | Director/Board Member | 63 | 25/01/23 |
David Hochman
CEO | Chief Executive Officer | 49 | 25/01/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 5 | -1.96% | 1 050 |
| 03/05/24 | 5.1 | -8.11% | 68,178 |
| 02/05/24 | 5.55 | +26.14% | 39,728 |
| 01/05/24 | 4.4 | -0.23% | 44,539 |
| 30/04/24 | 4.41 | +0.46% | 56,053 |
Delayed Quote Nasdaq, May 06, 2024 at 02:44 pm
More quotes
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.1
USD
Average target price
16.33
USD
Spread / Average Target
+220.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.24% | 183M | |
| +8.03% | 218B | |
| +7.23% | 184B | |
| +13.21% | 135B | |
| -0.46% | 62.38B | |
| +12.13% | 51.37B | |
| +4.81% | 50.9B | |
| +0.19% | 40.87B | |
| +2.68% | 36.28B | |
| +26.37% | 31.88B |
- Stock Market
- Equities
- OBIO Stock
